| HOME >> BIOLOGY >> TECHNOLOGY |
MARLBOROUGH, Mass., March 10, 2011 /PRNewswire/ -- Advanced Cell Technology, Inc. (“ACT”; OTC Bulletin Board: ACTC), a leader in the field of regenerative medicine, announced today that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has announced a positive opinion of ACT's human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells for designation as an orphan medicinal product for the treatment of Stargardt's disease. This opinion will now be forwarded by the EMA to the European Commission for their adoption, which should follow in coming weeks. This follows on the US Food & Drug Administration's granting of Orphan Drug Designation for the same program from ACT, last year.
"We are very pleased to receive this positive opinion for Orphan Drug Designation from the EMA for our hESC-derived RPE cells for the treatment of Stargardt's disease," said Gary Rabin, ACT's interim chairman and CEO. "There is currently no approved treatment for Stargardt's disease, and we are working diligently to move this European trial forward as quickly as possible."
Orphan Drug Designation by the European Commission provides regulatory and financial incentives for companies to develop and market therapies that treat a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the European Union (EU). In addition to a 10-year period of marketing exclusivity in the EU after product approval, Orphan Drug Designation provides companies with scientific advice and regulatory assistance from the EMA during the product development phase, direct access to centralized marketing authorization, as well as reductions in certain fees associated with the application and approval process.
About Stargardt's Disease Stargardt's disease or Stargardt's Macular Dystrophy is
'/>"/>
| SOURCE Advanced Cell Technology, Inc. Copyright©2010 PR Newswire. All rights reserved |
Related biology technology :
1. Mylans Matrix Receives FDA Approval Under PEPFAR for Zidovudine Tablets, 100 mg
2. Everist Genomics Laboratory Receives Approval From U.S. Regulatory Authorities For High Complexity Clinical Testing
3. EMD Serono Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application
4. Rensselaer professor Daniel Lewis receives NSF CAREER Award
5. Pacific Shore Holdings, Inc. Receives Symbol Change Approval From FINRA
6. Boston College receives W.M. Keck Foundation funding for nanoscale optical microscope
7. CMU Receives $1.2 Million NIH Grant To Develop Ethics, Policy Recommendations for Post-Conflict, Post-Disaster DNA ID Practices
8. Dr. Stefan Strauf of physics at Stevens receives NSF CAREER Award for quantum research
9. Onyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib; Company Initiates Rolling NDA Submission for Accelerated Approval
10. Arteriocyte Receives FDA Approval to Move Forward with Critical Limb Ischemia Trial
11. 3SBio Inc. Receives SFDA Approval for TPIAO Label Extension for the Treatment of ITP
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |